Effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on left ventricular myocardial DYsfunction in patients with type 2 DiAbetes mellitus and concentric left ventricular geometry. - Trial 2014-004683-38
Access comprehensive clinical trial information for 2014-004683-38 through Pure Global AI's free database. This Phase 3 trial is sponsored by Fondazione per il Tuo cuore onlus-ANMCO and is currently Completed. The study focuses on Type 2 Diabetes mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2014-004683-38
Phase 3
Completed
Trial Details
EU Clinical Trials Register • 2014-004683-38
Effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on left ventricular myocardial DYsfunction in patients with type 2 DiAbetes mellitus and concentric left ventricular geometry.
Study Focus
Sponsor & Location
Fondazione per il Tuo cuore onlus-ANMCO
Boehringer Ingelheim
Timeline & Enrollment
Phase 3
N/A
N/A
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
EU Clinical Trials Register
2014-004683-38
Non-Device Trial